Values First Advisors Inc. Reduces Position in Mirum Pharmaceuticals, Inc. $MIRM

Values First Advisors Inc. lessened its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 42.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,397 shares of the company’s stock after selling 7,027 shares during the quarter. Values First Advisors Inc.’s holdings in Mirum Pharmaceuticals were worth $868,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Cullen Frost Bankers Inc. bought a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $30,000. Eurizon Capital SGR S.p.A. bought a new stake in Mirum Pharmaceuticals in the 4th quarter worth $32,000. CIBC Private Wealth Group LLC bought a new stake in Mirum Pharmaceuticals in the 4th quarter worth $32,000. Quantbot Technologies LP purchased a new position in shares of Mirum Pharmaceuticals in the third quarter valued at about $33,000. Finally, Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period.

Mirum Pharmaceuticals Trading Up 0.6%

NASDAQ:MIRM opened at $107.77 on Tuesday. The company has a 50-day moving average price of $98.87 and a 200-day moving average price of $92.64. Mirum Pharmaceuticals, Inc. has a 12 month low of $47.89 and a 12 month high of $114.99. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The stock has a market cap of $6.57 billion, a price-to-earnings ratio of -7.92 and a beta of 0.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. During the same period in the previous year, the firm posted ($0.30) EPS. The company’s revenue for the quarter was up 43.3% on a year-over-year basis. Equities analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Analyst Ratings Changes

MIRM has been the subject of a number of analyst reports. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Wolfe Research began coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 price target on the stock. Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, June 8th. HC Wainwright reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $139.80.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $93.82, for a total transaction of $469,100.00. Following the sale, the chief financial officer directly owned 44,788 shares of the company’s stock, valued at approximately $4,202,010.16. The trade was a 10.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,594 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $101.95, for a total value of $264,458.30. Following the completion of the transaction, the senior vice president directly owned 5,835 shares of the company’s stock, valued at $594,878.25. This represents a 30.77% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,594 shares of company stock worth $3,608,758 over the last three months. Company insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.